VRTX vs. REGN

In the year-to-date period, VRTX achieves a 4.79% return, which is significantly higher than REGN's -4.32% return. Over the past 10 years, VRTX has outperformed REGN with an annualized return of 12.99%, while REGN has yielded a comparatively lower 4.94% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VRTX Sharpe Ratio is -0.11, which is higher than the REGN Sharpe Ratio of -1.17. The chart below compares the historical Sharpe Ratios of VRTX and REGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither VRTX nor REGN has paid dividends to shareholders.

The maximum VRTX drawdown since its inception was -91.77%, roughly equal to the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for VRTX and REGN. For additional features, visit the drawdowns tool.

Vertex Pharmaceuticals Incorporated (VRTX) has a higher volatility of 14.28% compared to Regeneron Pharmaceuticals, Inc. (REGN) at 9.43%. This indicates that VRTX's price experiences larger fluctuations and is considered to be riskier than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.